Glycosylated PD-1 Antibodies for Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting the PD-1/PD-L1 pathway in cancer treatment have limitations due to incomplete understanding of their pathophysiological function and regulatory mechanisms, and existing antibodies can induce autoimmune responses, necessitating the development of more selective and effective therapeutics.
Innovation Solution
Development of isolated monoclonal antibodies that selectively bind to glycosylated PD-1 at specific sites (N49, N58, N74, and N116) with enhanced affinity, such as STM418 and STM432, which compete for binding or mask glycosylation motifs to inhibit PD-1/PD-L1 interaction, thereby blocking cancer cell progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-PD-1 antibodies are used to block immunosuppression, then therapeutic efficacy is improved, but autoimmune responses are induced
Solution Approach 1:
The antibody is engineered to recognize a specific local feature (glycosylation at N49) on the PD-1 protein rather than binding to the entire protein structure. This localized recognition allows selective binding to glycosylated PD-1 while avoiding binding to unglycosylated forms, thereby achieving tumor-specific inhibition with reduced off-target autoimmune effects
Solution Approach 2:
The invention exploits a post-translational modification parameter (glycosylation status) to differentiate between target and non-target proteins. By designing the antibody to recognize the glycosylated form specifically, the therapy can distinguish between PD-1 on tumor-infiltrating T cells (which requires glycosylation for proper folding and function) and PD-1 on other immune cells, thus modulating the therapeutic window
2Reliability
If anti-PD-L1 antibodies are used to target cancer cells, then dual efficacy is achieved by blocking immunosuppression and reducing cell progression, but the pathophysiological function and regulatory mechanism remain incompletely defined
Solution Approach 1:
The invention performs preliminary research by systematically studying PD-1 glycosylation patterns and their functional implications before developing the therapeutic antibody. By identifying and characterizing the glycosylation sites (particularly N49) and their role in PD-1 function, the research establishes a mechanistic foundation that informs the subsequent antibody design and therapeutic development
Solution Approach 2:
The glycosylation moiety acts as an intermediary structure that the antibody recognizes instead of the PD-1 protein itself. This intermediary approach allows the antibody to bind with high specificity to glycosylated PD-1 while the underlying mechanism of glycosylation-dependent PD-1 function provides insight into the pathophysiology of the PD-1 pathway
Data Source
AI summary
Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.